-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ALKS-2680 in Type 1 Narcolepsy (Narcolepsy with Cataplexy)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ALKS-2680 in Type 1 Narcolepsy (Narcolepsy with Cataplexy) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ALKS-2680 in Type 1 Narcolepsy (Narcolepsy with Cataplexy)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ensartinib Hydrochloride in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ensartinib Hydrochloride in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ensartinib Hydrochloride in Non-Small Cell Lung Cancer Drug...
-
Company Insights
Innovation and Patenting activity of ALK-Abello AS Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of ALK-Abello AS Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ALKS-2680 in Type 2 Narcolepsy (Narcolepsy without Cataplexy)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ALKS-2680 in Type 2 Narcolepsy (Narcolepsy without Cataplexy) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ALKS-2680 in Type 2 Narcolepsy (Narcolepsy without Cataplexy)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – SH-748 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SH-748 in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SH-748 in Follicular Lymphoma Drug Details: SH-748 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – SH-748 in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SH-748 in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SH-748 in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – SH-748 in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SH-748 in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SH-748 in Refractory Chronic Lymphocytic Leukemia (CLL) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SH-748 in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SH-748 in Marginal Zone B-cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SH-748 in Marginal Zone B-cell Lymphoma Drug Details: SH-748 is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Pelcitoclax in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pelcitoclax in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pelcitoclax in Non-Small Cell Lung Cancer Drug Details: Pelcitoclax (APG-1252)...